Vascular dysfunction—The disregarded partner of Alzheimer's disease

Melanie D. Sweeney(University of Southern California), Axel Montagne(University of Southern California), Abhay P. Sagare(University of Southern California), Daniel A. Nation(University of Southern California), Lon S. Schneider(University of Southern California), Helena C. Chui(University of Southern California), Michael G. Harrington(Huntington Medical Research Institutes), Judy Pa(University of Southern California), Meng Law(University of Southern California), Danny J.J. Wang(University of Southern California), Russell E. Jacobs(University of Southern California), Fergus Doubal(Wellcome Centre for Human Neuroimaging), Joel Ramirez(Sunnybrook Health Science Centre), Sandra E. Black(Sunnybrook Health Science Centre), Maiken Nedergaard(University of Copenhagen), Helene Benveniste(Yale University), Martin Dichgans(Ludwig-Maximilians-Universität München), Costantino Iadecola(Cornell University), Seth Love(Southmead Hospital), Philip M. Bath(Nottingham University Hospitals NHS Trust), Hugh S. Markus(University of Cambridge), Rustam Al‐Shahi Salman(Wellcome Centre for Human Neuroimaging), Stuart M. Allan(Manchester Academic Health Science Centre), Terence J. Quinn(University of Glasgow), Rajesh N. Kalaria(Newcastle University), David J. Werring(National Hospital for Neurology and Neurosurgery), Roxana O. Carare(University of Southampton), Rhian M. Touyz(British Heart Foundation), Steven Williams(Wellcome Centre for Human Neuroimaging), Michael A. Moskowitz(Harvard University), Zvonimir S. Katušić(Mayo Clinic), Sarah E. Lutz(University of Illinois Chicago), Orly Lazarov(University of Illinois Chicago), Richard D. Minshall(University of Illinois Chicago), Jalees Rehman(University of Illinois Urbana-Champaign), Thomas P. Davis(University of Arizona), Cheryl L. Wellington(University of British Columbia), Hector M. González(University of California San Diego), Chun Yuan(University of Washington), Samuel N. Lockhart(Wake Forest University), Timothy M. Hughes(Wake Forest University), Christopher Chen(National University of Singapore), Perminder S. Sachdev(Department of Health and Aged Care), John T. O’Brien(University of Cambridge), Ingmar Skoog(University of Gothenburg), Leonardo Pantoni(University of Milan), Deborah Gustafson(State University of New York), Geert Jan Biessels(University Medical Center Utrecht), Anders Wallin(University of Gothenburg), Eric E. Smith(University of Calgary), Vincent Mok(Chinese University of Hong Kong), Adrian Wong(Chinese University of Hong Kong), Peter Passmore(Queen's University Belfast), Frederick Barkof(Amsterdam Neuroscience), Majon Muller(Amsterdam UMC Location Vrije Universiteit Amsterdam), Monique M.B. Breteler(University of Bonn), Gustavo C. Román(Houston Methodist), Édith Hamel(Montreal Neurological Institute and Hospital), Sudha Seshadri(Boston University), Rebecca F. Gottesman(Johns Hopkins University), Mark A. van Buchem(Leiden University Medical Center), Zoe Arvanitakis(Rush University Medical Center), Julie A. Schneider(Rush University Medical Center), Lester R. Drewes(University of Minnesota, Duluth), Vladimir Hachinski(Western University), Caleb E. Finch(University of Southern California), Arthur W. Toga(University of Southern California), Joanna M. Wardlaw(Wellcome Centre for Human Neuroimaging), Berislav V. Zloković(University of Southern California)
Alzheimer s & Dementia
January 1, 2019
Cited by 720Open Access
Full Text

Abstract

Increasing evidence recognizes Alzheimer's disease (AD) as a multifactorial and heterogeneous disease with multiple contributors to its pathophysiology, including vascular dysfunction. The recently updated AD Research Framework put forth by the National Institute on Aging-Alzheimer's Association describes a biomarker-based pathologic definition of AD focused on amyloid, tau, and neuronal injury. In response to this article, here we first discussed evidence that vascular dysfunction is an important early event in AD pathophysiology. Next, we examined various imaging sequences that could be easily implemented to evaluate different types of vascular dysfunction associated with, and/or contributing to, AD pathophysiology, including changes in blood-brain barrier integrity and cerebral blood flow. Vascular imaging biomarkers of small vessel disease of the brain, which is responsible for >50% of dementia worldwide, including AD, are already established, well characterized, and easy to recognize. We suggest that these vascular biomarkers should be incorporated into the AD Research Framework to gain a better understanding of AD pathophysiology and aid in treatment efforts.


Related Papers

No related papers found

Powered by citation graph analysis